Table 1 Summary of studies included in the quantitative analysis
| Â | Â | Â | N | % |
|---|---|---|---|---|
Total number of studies included | 96 | Â | ||
| Â | Â | Original articles | 82 | 85.4 |
| Â | Â | Abstracts | 14 | 14.6 |
Year of publication | ||||
| Â | Â | 2009 | 6 | 6.3 |
| Â | Â | 2010 | 7 | 7.3 |
| Â | Â | 2011 | 8 | 8.3 |
| Â | Â | 2012 | 12 | 12.5 |
| Â | Â | 2013 | 17 | 17.7 |
| Â | Â | 2014 | 29 | 30.2 |
| Â | Â | 2015 | 17 | 17.7 |
Global distribution of location of institutions of selected studies | ||||
| Â | Â | North America | 54 | 56.3 |
| Â | Â | Europe | 21 | 21.9 |
| Â | Â | Asia | 18 | 18.7 |
| Â | Â | Australia/Africa/South America (1 each) | 3 | 3.1 |
Single vs multi-institutional | ||||
| Â | Â | Single institution | 83 | 86.5 |
| Â | Â | Multi-institutional | 13 | 13.5 |
Type of study | ||||
| Â | Â | Retrospective series | 54 | 56.3 |
| Â | Â | Phase 2 studies | 22 | 22.9 |
| Â | Â | Prospective series | 11 | 11.5 |
| Â | Â | Phase 1 studies | 5 | 5.2 |
| Â | Â | Phase 1/2 studies | 3 | 3.1 |
| Â | Â | Phase 3 studies | 1 | 1 |
Criteria for resectability | ||||
| Â | Â | NCCN/AHPBA/SSO/SSAT consensus | 38 | 39.6 |
| Â | Â | MD Anderson | 8 | 8.3 |
| Â | Â | Other | 29 | 30.2 |
| Â | Â | Not mentioned | 21 | 21.9 |
Number of studies of each local/anatomical stage | ||||
| Â | Â | Resectable | 18 | 18.8 |
| Â | Â | Borderline resectable (BR) | 15 | 15.6 |
| Â | Â | Locally advanced unresectable (LA) | 29 | 30.2 |
| Â | Â | RÂ +Â BR | 5 | 5.2 |
| Â | Â | BRÂ +Â LA | 24 | 25 |
| Â | Â | RÂ +Â BRÂ +Â LA | 5 | 5.2 |
Number of patients in each anatomical stage | ||||
| Â | Â | Resectable | 1056 | 19.1 |
| Â | Â | Borderline resectable (BR) | 935 | 16.9 |
| Â | Â | Locally advanced unresectable (LA) | 1840 | 33.3 |
| Â | Â | RÂ +Â BR | 202 | 3.7 |
| Â | Â | BRÂ +Â LA | 1014 | 18.4 |
| Â | Â | RÂ +Â BRÂ +Â LA | 473 | 8.6 |
Criteria for of radiology response assessment | ||||
| Â | Â | RECIST | 48 | 50 |
| Â | Â | WHO | 5 | 5.2 |
| Â | Â | Other | 2 | 2.1 |
| Â | Â | Not mentioned | 41 | 42.7 |
Criteria for toxicity assessment | ||||
| Â | Â | NCI CTCAE | 43 | 44.8 |
| Â | Â | WHO | 5 | 5.2 |
| Â | Â | RTOG | 2 | 2.1 |
| Â | Â | Not mentioned/not applicable | 46 | 47.9 |
Type of neoadjuvant therapy | ||||
| Â | Â | Chemoradiotherapy | 33 | 34.4 |
| Â | Â | Chemotherapy alone | 20 | 20.8 |
| Â | Â | Chemotherapy with chemoradiation | 41 | 42.7 |
| Â | Â | Radiation alone | 2 | 2.1 |
Chemotherapy drugs | ||||
| Â | Â | Monotherapy (Gem/5FU/Cape/UFT/Cis) | 26 | 27.1 |
| Â | Â | FOLFIRINOX | 20 | 20.8 |
| Â | Â | Gemcitabine + oxaliplatin* | 8 | 8.3 |
| Â | Â | Gemcitabine or 5FUÂ +Â cisplatin | 7 | 7.3 |
| Â | Â | Gemcitabine + Docetaxel | 3 | 3.1 |
| Â | Â | GTX (gemcitabine, taxane, capecitabine) | 6 | 6.3 |
| Â | Â | Gem + biologic (bevacizumab, cetuximab) | 3 | 3.1 |
| Â | Â | Gem + S1 | 5 | 5.2 |
| Â | Â | Gem + Nab-paclitaxel | 2 | 2.1 |
| Â | Â | 5FUÂ +Â cisplatin + interferon | 1 | 1 |
| Â | Â | Multiple | 11 | 11.5 |
| Â | Â | Not mentioned | 2 | 2.1 |
| Â | None | 2 | 2.1 | |
Radiotherapy | ||||
| Â | Â | Yes | 76 | 79.2 |
| Â | Â | No | 20 | 20.8 |